Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Genipin SCHEMBL22557817 | 1.00 | PTPN1 (0.70) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL25807077 | 1.00 | PTPN1 (0.70) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL16697983 | 1.00 | PTPN1 (0.70) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL20083921 | 1.00 | PTPN1 (0.70) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL5075862 | 1.00 | PTPN1 (0.70) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL34249 | 1.00 | PTPN1 (0.70) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL9609096 | 1.00 | PTPN1 (0.70) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL13526030 | 1.00 | PTPN1 (0.70) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL5134206 | 0.99 | PTPN1 (0.69) | PTPN1MEN1KMT2ATLR4 | |
| Genipin SCHEMBL19356583 | 0.97 | PTPN1 (0.71) | PTPN1MEN1KMT2ATLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
| EP-1045841-B1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | CHOONGWAE PHARMA CORP (KR) | 2002-12-04 | — | — | EP | disclosed |
| US-6262083-B1 | Genipin derivative having liver protection activity | CHOONGWAE PHARMA CORPORATION (KR) | 2001-07-17 | — | — | US | disclosed |
| EP-1045841-A1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | Choongwae Pharma Corporation (KR) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999023090-A1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | CHOONGWAE PHARMA CORPORATION (KR) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | HCCS, HAVCR2, PYGL | PTPN1 3880/4885MEN1 3943/4885KMT2A 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.